Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
CMPK1	51727	GEMCITABINE	CHEMBL888	inhibitor	DrugBank	15550676, 17565005, 17000136, 16041392
CMPK1	51727	CHEMBL307679	CHEMBL307679		DrugBank	17139284, 17016423, 10592235
CMPK1	51727	URIDINE_DIPHOSPHATE	CHEMBL130266		DrugBank	17139284, 17016423, 10592235

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
CMPK1	rs1044457	CC	gemcitabine	efficacy	yes	Associated with longer overall survival and time to progression. Stats corrected with the false-discovery rate for candidate SNPs and Bonferroni method (p<0.05 was considered significant).	Genotype CC is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT.	22838950	981237722
CMPK1	rs7543016	CC	gemcitabine	efficacy	yes	Associated with longer time to progression. Stats corrected with the false-discovery rate for candidate SNPs and Bonferroni method (p<0.05 was considered significant).	Genotype CC is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CG + GG.	22838950	981237819
CMPK1	rs35687416	GG	gemcitabine	efficacy	yes	Associated with longer overall survival and time to progression. Stats corrected with the false-discovery rate for candidate SNPs and Bonferroni method (p<0.05 was considered significant).	Genotype GG is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes GT + TT.	22838950	981237767
CMPK1	rs3925058	AA	gemcitabine	efficacy	no	Not statistically significantly associated with time to progression. Stats corrected with the false-discovery rate for candidate SNPs and Bonferroni method (p<0.05 was considered significant).	Genotype AA is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AG + GG.	22838950	981237814
CMPK1	rs11211524	A	gemcitabine	"efficacy","toxicity"	no	SNPs were selected based on prior literature and no alleles demonstrated any association with neurotoxicity or overall survival.	Allele A is not associated with response to gemcitabine and paclitaxel in women with Breast Neoplasms as compared to allele C.	24361227	1184086216
CMPK1	rs4492666	A	gemcitabine	"efficacy","toxicity"	no	SNPs were selected based on prior literature and no alleles demonstrated any association with neurotoxicity or overall survival.	Allele A is not associated with response to gemcitabine and paclitaxel in women with Breast Neoplasms as compared to allele C.	24361227	1184086224
CMPK1	rs12090346	CC	cisplatin	efficacy	no	The authors analyzed the effect of genotype in CMPK1 on overall survival in patients treated with gemcitabine/cisplatinum (n=139) and in patients treated with taxane/cisplatinum (n= 159). After adjustment for confounding variables (weight loss, ECOG performance status, 2nd line treatment and radiation therapy) the effect of the genotype at rs12090346 was not found to be significantly associated with shorter survival in any patient.	Genotype CC is not associated with response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT.	21642870	1183960621
CMPK1	rs1044457	CC	cisplatin	efficacy	no	The authors analyzed the effect of genotype in CMPK1 on overall survival in patients treated with gemcitabine/cisplatinum (n=139) and in patients treated with taxane/cisplatinum (n= 159). After adjustment for confounding variables (weight loss, ECOG performance status, 2nd line treatment and radiation therapy) the effect of the genotype at rs1044457 was not found to be significantly associated with shorter survival in any patient.	Genotype CC is not associated with response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT.	21642870	1183960626
CMPK1	rs4492666	CC	cisplatin	efficacy	yes	The authors analyzed the effect of genotype in CMPK1 on overall survival in patients treated with gemcitabine/cisplatinum (n=139) and in patients treated with taxane/cisplatinum (n= 159). After adjustment for confounding variables (weight loss, ECOG performance status, 2nd line treatment and radiation therapy) the effect of the CC genotype became significantly associated with shorter survival but only in patients treated with gemcitabine. In addition, when the CC genotype was combined with the TT genotype at rs2284449, the AA genotype at rs2044139, the AA genotype at rs232043, or the TT genotype at rs720106, overall survival was significantly shorter for patients treated with gemcitabine.	Genotype CC is associated with decreased response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AC.	21642870	1183960529
CMPK1	rs11211524	CC	cisplatin	efficacy	yes	The authors analyzed the effect of genotype in CMPK1 on overall survival in patients treated with gemcitabine/cisplatinum (n=139) and in patients treated with taxane/cisplatinum (n= 159). After adjustment for confounding variables (weight loss, ECOG performance status, 2nd line treatment and radiation therapy) the effect of the CC genotype became significantly associated with shorter survival but only in patients treated with gemcitabine.	Genotype CC is associated with decreased response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AC.	21642870	1183960596